Telix Pharmaceuticals Ltd ADR (NASDAQ:TLX) shares rose 6.7% on Friday following the company’s announcement that the U.S. Food and Drug Administration has accepted its resubmitted New Drug Application for TLX101-Px. The FDA has established a Prescription Drug User Fee Act - PDUFA - target date of September 11, 2026, for the review.
TLX101-Px, which is also marketed as Pixclara and is chemically referred to as Floretyrosine F 18, is an investigational PET imaging agent developed to distinguish recurrent or progressive glioma from treatment-related changes. The product’s intended use spans both adult and pediatric patients, according to the company disclosure.
The candidate has been granted Orphan Drug and Fast Track designations by the FDA, regulatory statuses that Telix and its supporters say could affect the development and review pathway. International clinical practice guidelines, including those from the National Comprehensive Cancer Network - NCCN - already recommend neuroimaging of glioma using 18F-FET, a context cited in support of the agent’s clinical relevance.
"There remains a critical unmet need in improving our ability to image residual glioma after treatment," said Thomas Hope, Vice Chair, Department of Radiology and Biomedical Imaging at University of California, San Francisco.
Patrick Wen, E. Antonio Chiocca Family Endowed Chair in Neuro-Oncology at Mass General Brigham Cancer Institute, noted that "distinguishing tumor progression from treatment-related change remains one of the most challenging aspects of glioma care."
Telix’s leadership framed the FDA acceptance as a material step in the program. "The FDA’s acceptance of the NDA resubmission represents an important milestone for the company," said Kevin Richardson, CEO of Telix Precision Medicine. The company also disclosed that its fiscal 2026 guidance does not assume any revenue contribution from TLX101-Px.
On the broker side, H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Telix with a $20.00 price target. Burns commented that the FDA’s acceptance addresses a significant unmet medical need and highlighted the product’s regulatory designations as notable.
This regulatory development has translated into a measurable market reaction while the company and investors await the September 2026 PDUFA decision and any further regulatory communications.